跳至主要内容
临床试验/NCT02084069
NCT02084069已完成3 期

Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair

Urmia University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2013年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
58
试验地点
1
主要终点
Atrial Fibrillation Incidence After Open Cardiac Valve Repair

研究概览

简要总结

The purpose of the investigation is to determine whether Atrovastatin as anti-inflammatory agent can be effective in preventing from atrial fibrillation incidence in patients whom undergone open cardiac surgery for their heart valve repair.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
25 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Greater than 25 y/o
  • No occurrence of intra- or post-operative cardiopulmonary arrest
  • Not consuming drugs affecting atrial rhythm
  • Having sinus rhythm before surgery
  • Lack of paroxysmal atrial fibrillation history
  • Only undergo heart valve surgery
  • Lack of considerable heart ischemia needed atorvastatin use
  • Routine cares in ward, post-operative ward, and intensive care unit were done

排除标准

  • Lesser than 25 y/o
  • History of atrial fibrillation
  • History of taking anti-arrhythmic drugs
  • History of implementing pacemakers
  • Severe heart failure
  • Renal failure
  • Hepatic failure
  • Severe pulmonary diseases
  • Heart block or bradyarrhythmia
  • Routine cares in ward, post-operative ward, and intensive care unit were not done
  • Performing concomitant cardiac surgery except valve repair
  • Having considerable heart ischemia needed atorvastatin use

研究组 & 干预措施

Treatment

Active Comparator

Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery

干预措施: Atorvastatin (Drug)

结局指标

主要结局

Atrial Fibrillation Incidence After Open Cardiac Valve Repair

时间窗: Within 5 days after open cardiac valve repair

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验